• N/A
    Market Cap
  • -72.04%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
Income Statement
Total Operating Revenue
3,000
N/A
Cost of Revenue
N/A
N/A
Gross Profit
3,000
N/A
Sales and Marketing Expense
45,000
N/A
Research and Development Expense
-813,000
N/A
Depreciation and Amortization Expense
100,000
N/A
Total Operating Expenses
2.6M
N/A
Operating Profit
-2.6M
N/A
Interest Income
610,000
N/A
Interest Expense
-2.1M
N/A
Interest Income and Expense and Net
-1.5M
N/A
Total Nonoperating Income and Expense
-2.1M
N/A
Income before Taxes
-4.7M
N/A
Income Taxes
N/A
N/A
Extraordinary Items
N/A
N/A
Net Income
-4.7M
N/A
Net Income from Continuing Operations Applicable to Common
-4.7M
N/A
Basic EPS and Net Income
-0.06
N/A
Diluted EPS and Net Income
-0.06
N/A
Basic Weighted Average Shares
73.0M
N/A
Diluted Weighted Average Shares
73.0M
N/A
Balance Sheet
Cash and Cash Equivalents
428,000
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
428,000
N/A
Total Current Assets
15.5M
N/A
Accumulated Depreciation
1.7M
N/A
Property and Plant and Equipment and Net
3.1M
N/A
Total Long-Term Assets
5.2M
N/A
Total Assets
20.8M
N/A
Income Taxes Payable
21.0M
N/A
Total Short-Term Debt
8.3M
N/A
Total Current Liabilities
34.8M
N/A
Total Long-Term Debt
7.7M
N/A
Total Long-Term Liabilities
10.9M
N/A
Total Liabilities
45.7M
N/A
Retained Earnings
-37.8M
N/A
Total Stockholders Equity
-24.9M
N/A
Total Shares Outstanding
76.0M
N/A
Cash Flow
Cash from Operating Activities
-3.0M
N/A
Capital Expenditures
N/A
N/A
Cash from Investing Activities
-13.5M
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
17.6M
N/A
Financials Ratio
Gross Margin
N/A
N/A
Operating Margin
N/A
N/A
Return on Assets
N/A
N/A
Return on Equity
N/A
N/A
Revenue Growth
N/A
N/A
Current Ratio
N/A
N/A
Cash Ratio
N/A
N/A
Debt-to-Equity Ratio
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow